Separately, Robert W. Baird started coverage on shares of Cue Biopharma in a report on Thursday, July 25th. They issued an outperform rating and a $13.00 target price on the stock.
Shares of CUE opened at $8.82 on Tuesday. Cue Biopharma has a one year low of $4.16 and a one year high of $9.94. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average price is $8.16 and its 200 day moving average price is $8.03.
A number of institutional investors and hedge funds have recently made changes to their positions in CUE. BNP Paribas Arbitrage SA raised its holdings in Cue Biopharma by 1,159.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,805 shares of the company’s stock worth $29,000 after acquiring an additional 3,503 shares during the period. Strs Ohio raised its holdings in Cue Biopharma by 500.0% in the 2nd quarter. Strs Ohio now owns 15,000 shares of the company’s stock worth $134,000 after acquiring an additional 12,500 shares during the period. Sigma Planning Corp raised its holdings in Cue Biopharma by 13.6% in the 2nd quarter. Sigma Planning Corp now owns 47,805 shares of the company’s stock worth $430,000 after acquiring an additional 5,706 shares during the period. Northern Trust Corp raised its holdings in Cue Biopharma by 2.0% in the 2nd quarter. Northern Trust Corp now owns 204,555 shares of the company’s stock worth $1,839,000 after acquiring an additional 3,970 shares during the period. Finally, BlackRock Inc. raised its holdings in Cue Biopharma by 21.3% in the 2nd quarter. BlackRock Inc. now owns 1,148,126 shares of the company’s stock worth $10,321,000 after acquiring an additional 201,986 shares during the period. Hedge funds and other institutional investors own 19.93% of the company’s stock.
Cue Biopharma Company Profile
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Read More: Management Fee
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.